NanoMed Targeting Systems (NTS), an early stage company founded in Oklahoma City, seeks to develop, manufacture and market targeted delivery systems for nanomedicines. Its platform technology delivers magnetic nanoformulations carrying therapeutic payload(s), targeted by a non-invasive proprietary magnetic guiding system. NTS is currently developing Targeting Systems to: a) treat early AF, the most common cardiac arrhythmia worldwide, and b) prevent POAF.
- AF is the most common cardiac arrhythmia, affecting 5 million Americans (15 million in the Western world), with more than 160,000 new cases diagnosed in the U.S. each year
- AF is such a significant healthcare problem in the U.S. that the Senate acknowledged the high costs to our nation and the 1:4 risk that those older than 40 will develop AF in their lifetime. (112th Congress, 1st Session, S. RES 243, July 29, 2011)
- RF Ablation – the leading treatment of AF – has higher risk and cost and about 50% of the patients need another procedure within 5 years.
- Post-Operative AF currently does not have a reliable prevention.